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The sPLA 2 family in mammals comprises 10 isozymes, all of which have a conserved Ca 2ϩ -binding loop and a catalytic site with a His/Asp catalytic dyad (1, 2) . The genes for 6 enzymes (IIA, IIC, IID, IIE, IIF, and V), which are often referred to as group II subfamily sPLA 2 s, are mapped to the same chromosomal locus. Accumulating evidence suggests that several sPLA 2 s play a crucial role in the regulation of arachidonic acid (AA) metabolism in an autocrine, paracrine or juxtacrine manner (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) .
sPLA 2 -IIA is abundantly present at various inflamed sites and is upregulated in various cells and tissues in response to proinflammatory stimuli (9 -12) . In addition to its potent bactericidal activity (19 -21) and potential anti-tumorigenic role (22) , this enzyme promotes stimulus-induced release of AA, which is in turn supplied to cyclooxygenase (COX) enzymes for augmented PG generation (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . sPLA 2 -IIA can elicit AA release from activated cells through the HSPGshuttling pathway (4, 7) , in which the enzyme binds to the HSPG glypican and is then sorted into cytoplasmic punctate and perinuclear compartments that are assumed to be rich in anionic or oxidized phospholipids (3) (4) (5) (6) (7) (8) (9) (10) . Phospholipids in these compartments may also be enriched in AA, since the enzyme often causes AAselective release (4, 7) . Other heparin-binding sPLA 2 s such as sPLA 2 -IID (8, 23, 24) and -V (4 -8) , which are also stimulus-inducible (24, 25) , also utilize this HSPG-shuttling pathway. In contrast, sPLA 2 -X (7, 8, 17, 18) , as well as sPLA 2 -V in certain situations (8, (13) (14) (15) (16) , is capable of releasing AA even from resting cells by acting on the phosphatidylcholine (PC)-rich external plasma membrane with no dependence on HSPG. Elevated expression of sPLA 2 -X in some colorectal tumors implicates this enzyme in the development of cancer (26) . sPLA 2 -IIE is a recently identified group II subfamily isozyme that shows the highest homology with sPLA 2 -IIA and -IID (27, 28) . The in vitro enzymatic properties (e.g., substrate specificity, optimal pH, and sPLA 2 inhibitor sensitivity) of human sPLA 2 -IIE are reported to be similar to human sPLA 2 -IIA and -IID (27, 28) . In this study, the AA-releasing and PGE 2 -biosynthetic functions of human sPLA 2 -IIE were investigated in mammalian cells. The enzyme was found to promote stimulus-induced AA release and subsequent eicosanoid generation in a manner similar to those of other related heparin-binding sPLA 2 isozymes. Moreover, sPLA 2 -IIE was found to be an inducible enzyme in response to proinflammatory stimuli.
MATERIALS AND METHODS
Materials. Establishment, culture and activation of HEK293 (Human Science Research Resources Bank) and RBL-2H3 (Riken Cell Bank) transfectants were performed as described previously (4 -8) . Construction of the synthetic human sPLA 2 -IIE cDNA (28) will be described elsewhere.
Heparin binding. Binding of human sPLA 2 -IIE to heparinSepharose (Amersham Pharmacia Biotech) was assessed as described previously (3, 4) . Briefly, approximately 25 ml of culture supernatants of HEK293 cells transfected with human sPLA 2 -IIE were applied to a heparin-Sepharose column (1 ϫ 5 cm) preequilibrated with 10 mM Tris-HCl, pH 7.4, containing 150 mM NaCl (TBS) at a flow rate of 20 ml/h. After extensive washing with TBS, the bound proteins were eluted using 10 mM Tris-HCl, pH 7.4, with a 0.15-1 M NaCl gradient. PLA 2 activity in each fraction was measured as described above. Sulfate-Cellulofine column (Seikagaku Kogyo) was performed in a similar way.
RT-PCR/Southern blotting. Synthesis of cDNA was performed using 1 g of total RNA from mouse tissues and AMV reverse transcriptase, according to the manufacturer's instructions supplied with the RNA PCR kit (Takara Biomedicals). Subsequent amplification of the cDNA fragments for mouse sPLA 2 -IIE was performed using 1 l of the reverse-transcribed mixture as a template with specific oligonucleotide primers (Greiner) as follows: mIIE-5Ј primer 5Ј-ATG AAA CCT CCC ATT GCG CTG-3Ј and mIIE-3Ј primer 5Ј-TCA GCA GGG TGG GGT GGG CCC AG-3Ј. The PCR condition was 94°C for 30 s and then 35 cycles of amplification at 94°C for 5 s and 68°C for 4 min, using the Advantage cDNA polymerase mix (Clontech). Expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was assessed by 25 cycles of PCR amplification using specific primers (Clontech). The PCR products were analyzed by 1% agarose gel electrophoresis with ethidium bromide. The gels were further subjected to Southern blot hybridization using mouse sPLA 2 -IIE cDNA as a probe, as described previously (29) .
Confocal laser microscopy. Cells grown on collagen-coated cover glasses (Iwaki Glass) were fixed with 3% paraformaldehyde for 30 min in phosphate-buffered saline (PBS). After three washes with PBS, the fixed cells were sequentially treated with 1% bovine serum albumin (for blocking) and 1% saponin (for permeabilization) in PBS for 1 h, with anti-human or mouse sPLA 2 -IIE antibody (1:500 dilution) (30) dilution; Zymed) for 1 h. After six washes with PBS, the cells were mounted on glass slides using Perma Fluor (Shandon), and the sPLA 2 signal was visualized using a laser scanning confocal microscope (IX70; Olympus), as described previously (6) .
LPS treatment of mice. LPS (Salmonella minnesota Re 595; Sigma) (5 mg/kg) was injected intraperitoneally to 4-week-old male C57BL/6 mice (Nippon Bio-Supply Center). After 24 h, mice were sacrificed by bleeding, their organs were removed, and RNA was extracted by homogenization in TRIZOL reagent (Life Technologies) using 10 strokes of a Potter homogenizer at 1000 rpm.
Mouse ear topical dermatitis. Five repeated topical applications of 2,4-dinitrobenzene (DNFB) to the ears of BALB/c, but not C57BL/6, mice result in contact hypersensitivity of the ears as well as significant elevation of serum IgE level, accompanied by the increased T H1 response for the onset of skin dermatitis and the T H2 response in the lymph node (31) . Briefly, the ears of BALB/c mice (Nippon Bio-Supply Center, Tokyo, Japan) were painted with 25 l of 0.15% (w/v) DNFB or vehicle (acetone:olive oil 3:1) once a week. The ears were removed 24 h after the fifth painting and subjected to RNA extraction. Replicate ear sections were fixed by formalin, embedded in paraffin and stained with hematoxylin and eosin to verify the progress of inflammation. All the procedures and analyses of other parameters are detailed elsewhere (31) .
Other procedures. Northern blotting, Western blotting, and in vitro sPLA 2 assay were performed as described previously (4 -8) . Data were analyzed by Student's t test. Results are expressed as the mean Ϯ SE, with P ϭ 0.05 as the limit of significance.
RESULTS
Enzymatic properties of human sPLA 2 -IIE. cDNA for human sPLA 2 -IIE was transfected into HEK293 cells to establish genetisin-resistant stable transfectants. The expression of the enzyme in the transfectants was assessed by enzyme activity (Fig. 1A) and Northern blotting (see Fig. 2D ). PLA 2 activity on phosphatidylethanolamine (PE) in the culture supernatant of cells transfected with human sPLA 2 -IIE was greatly elevated to a level comparable to that of cells transfected with several other human sPLA 2 s (Fig. 1B) . Mouse sPLA 2 -IIE exhibited very poor PLA 2 activity under the same assay condition (Fig. 1B) , in line with previous observations (27, 28) . This species difference is noteworthy because the enzymatic activity of other sPLA 2 s, including IB, IIA, IIC, V, and X, did not show such a species-related difference (4 -8). Human sPLA 2 -IIE hydrolyzed PE in marked preference to PC, as did human sPLA 2 -IIA and -IID, whereas human sPLA 2 -V and -X hydrolyzed both substrates efficiently (Fig. 1A) .
When the pooled culture supernatant of human sPLA 2 -IIE-expressing cells was applied to heparinSepharose (Fig. 1B) and sulfate-Cellurofine (Fig. 1C cells, which were stimulated for 4 h in medium containing 10% FCS with or without 1 ng/ml IL-1␤, were subjected to RNA blotting using COX-2 and hIIE cDNAs as probes. (E) Effect of heparin. Control and hIIE-transfected cells were incubated with 400 g/ml heparin overnight, and PGE 2 generation 4 h after incubation with 10% FCS plus 1 ng/ml IL-1␤ in the continued presence of heparin was examined.
the enzyme, as assessed by its activity, bound to the columns under conditions where sPLA 2 -IIA, -IID and -V bound entirely (3, 4, 8, 16) . The bound enzyme was eluted from these columns with a buffer containing 0.3-0.4 M NaCl (Figs. 1B and 1C) . Applying the flowthrough fractions to the columns again resulted in partial absorption of the enzyme, which was eluted with the same concentrations of NaCl (data not shown). As shown in Fig. 1D , approximately 80% of the enzyme activity was detected in the supernatants and the remaining 20% in the membrane-bound fraction that was solubilized with 1 M NaCl. In comparison, approximately 80, 50, and 40% of human sPLA 2 -IIA, IID, and V, respectively, were distributed in the NaClextractable fraction, whereas human sPLA 2 -X was largely secreted into the medium (Fig. 1D) . Given the fact that the membrane distribution of sPLA 2 -IIA, -IID, and -V reflects their association with HSPG on cell surface (3) (4) (5) (6) (7) (8) , these results indicate that human sPLA 2 -IIE has a significant affinity for heparin and cell surface HSPG, although it is weaker than that of sPLA 2 -IIA, -IID, and -V.
AA release and eicosanoid generation by sPLA 2 (Fig. 2A) . This fatty acidreleasing profile of human sPLA 2 -IIE was similar to that of sPLA 2 -IIA and -IID, which increased IL-1␤-dependent, [ 3 H]AA-selective release (3) (4) (5) (6) (7) (8) , but was distinct from that of sPLA 2 IL-1␤-stimulated [ 3 H]AA release by human sPLA 2 -IIE-expressing cells reached a peak by 4 h (Fig. 2B) , with concomitant production of PGE 2 (Fig. 2C ). This PGE 2 generation was blunted by the COX-2-selective inhibitor, NS-398 (data not shown), indicating a functional linkage between sPLA 2 -IIE and COX-2. As shown in Fig. 2D , human sPLA 2 -IIE-expressing cells expressed more COX-2 than control cells after IL-1␤ stimulation. Human sPLA 2 -V (Fig. 2D ) and -IIA (data not shown) also increased COX-2 expression (6, 7). Thus, like other HSPG-binding sPLA 2 s (IIA, IID and V) (4 -8), human sPLA 2 -IIE is capable of augmenting IL-1␤-stimulated AA-selective release and attendant COX-2-mediated delayed PGE 2 generation. Treating the cells with heparin, which solubilizes the HSPGbound form of sPLA 2 from cell surfaces (4, 6, 8, 9) , markedly reduced PGE 2 generation by human sPLA 2 -IIE (Fig. 2E) , further implying that AA release by this enzyme occurs largely through the HSPG-dependent mechanism.
A23187-induced immediate [ 3 H]AA release was also markedly elevated in human sPLA 2 -IIE-transfected cells relative to replicate control cells (Fig. 3A) . When COX-1 was transfected, A23187-induced immediate (Fig. 3B) , but not IL-1␤-induced delayed (data not shown), PGE 2 production was markedly augmented in human sPLA 2 -IIE-expressing cells compared with replicate control cells. Thus, human sPLA 2 -IIE can supply the substrate AA to COX-1 for immediate PGE 2 production.
To assess whether human sPLA 2 -IIE secreted from cells can influence PG generation by neighboring cells through the transcellular route (5), cells expressing human sPLA 2 -IIE were cocultured with cells expressing the downstream enzymes COX-2 and microsomal PGE 2 synthase (mPGES), and IL-1␤-stimulated generation of PGE 2 was examined. As shown in Fig. 3C , PGE 2 production by coculture of human sPLA 2 -IIE- repeated treatments with DNFB (B) were subjected to RT-PCR for mouse sPLA 2 -IIE (35 cycles), which was visualized by Southern hybridization using mouse sPLA 2 -IIE cDNA probe, and GAPDH (25 cycles), which was detected in agarose gels by ethidium bromide staining.
expressing cells and COX-2-expressing cells was several-fold higher than that produced by each type of cells alone. Introduction of mPGES, which lies downstream of COX-2 in the PGE 2 -biosynthetic pathway (32) , further increased this transcellular pathwaymediated PGE 2 production. Thus, human sPLA 2 -IIE produced by one cell can act on another COX-2-expressing cell in a paracrine manner to augment PGE 2 production by the latter.
Mouse sPLA 2 -IIE was unable to elicit these responses in HEK293 cells under any of the conditions tested (8) . However, when it was transfected into RBL-2H3 cells, IgE/antigen-dependent production of LTC 4 was severalfold higher than that observed in replicate control cells, reaching a level comparable to that induced by replicate mouse sPLA 2 -IID-transfected cells (Fig. 4A) . Thus, mouse sPLA 2 -IIE can be coupled with endogenous 5-lipoxygenase for LTC 4 biosynthesis in RBL-2H3 cells. Moreover, mouse sPLA 2 -IIE, like sPLA 2 -IID, enhanced IgE/Ag-induced ␤-hexosaminidase (␤-HEX) exocytosis by RBL-2H3 transfectants (Fig. 4B) .
Subcellular localization of sPLA 2 -IIE. We next performed confocal laser microscopy in order to assess the subcellular distribution of sPLA 2 -IIE in HEK293 transfectants. As shown in Fig. 5 , both mouse and human sPLA 2 -IIEs were distributed in punctate compartments throughout the cytoplasm. This punctate staining pattern was also observed with cells expressing other HSPG-binding sPLA 2 s, such as sPLA 2 -IIA and IID, but not with cells expressing sPLA 2 -X, a HSPG-nonbinding enzyme (6, 8, 10) .
Induction of sPLA 2 -IIE during inflammation. As examined by RT-PCR/Southern blotting, the expression of sPLA 2 -IIE in several mouse tissues, which was low under basal conditions, was markedly increased 24 h after intraperitoneal administration of LPS (Fig.  6A) . sPLA 2 -IIE expression was also markedly increased in the ears of mice after five repeated treatments with DNFB (Fig. 6B) , an experimental atopic dermatitis model.
DISCUSSION
Current evidence suggests that the AA-releasing function of various sPLA 2 s in mammalian cells are crucially influenced by the ability of the enzymes to interact with PC-rich membrane (8, (13) (14) (15) (16) (17) (18) , HSPG (3) (4) (5) (6) (7) (8) , and the sPLA 2 receptor (33, 34) . Several group II subfamily sPLA 2 enzymes (IIA, IID and V) have been implicated in the inflammatory and immune responses, since they are expressed in immune regulatory cells and are up-regulated by various cytokines and immunological stimuli (9 -13, 24, 25) . However, the regulatory functions of more recently cloned sPLA 2 s (IIE, IIF, III and XII) remain unknown. sPLA 2 -IIE, a new member of the group II subfamily sPLA 2 s that is closely related structurally to sPLA 2 -IIA and -IID, is reportedly expressed at relatively low levels in restricted tissues (27, 28) . We herein show that this novel group II sPLA 2 is an additional inducible regulator of AA metabolism that may play a role in the inflammatory process. The modes of action of human sPLA 2 -IIE resemble those of its closest relatives sPLA 2 -IIA and -IID in several ways. First, the enzymatic properties of these three group II enzymes are similar ( Fig. 1) (27, 28) . Second, these enzymes bind anionic heparin-or sulfate-enriched resins (Figs. 1B  and 1C) , even though the heparin affinity of sPLA 2 -IIE is lower than that of sPLA 2 -IIA, -IID and -V (IIA Ͼ IID Ͼ V Ͼ IIE in order, consistent with their calculated pI values of ϳ9. 4, 8.8, 8.5 , and 8.0, respectively). Accordingly, a low, but significant, portion of human sPLA 2 -IIE expressed in HEK293 cells is associated with HSPG on the cell surface (Fig. 1D) . Third, human sPLA 2 -IIE augments stimulus-induced, AA-selective release in HEK293 transfectants in a manner similar to sPLA 2 -IIA and -IID (4, 7) but not to sPLA 2 -X, which causes stimulus-independent, fatty acid-nonselective release (7, 8) . Fourth, human sPLA 2 -IIE induces the expression of endogenous COX-2 and attendant delayed PGE 2 generation (Figs. 2C and 2D) , an event peculiar to HSPG-binding group II subfamily sPLA 2 s (6 -8). Moreover, PGE 2 generation by human sPLA 2 -IIE is markedly suppressed by exogenous heparin (Fig.  2E) , which solubilizes the cell surface HSPG-bound form of sPLA 2 s (3, 4, 6, 8) . Although the mechanisms for COX-2 induction by HSPG-binding sPLA 2 s are unclear, the requirement for their catalytic activity (7) suggests that certain reaction products spatiotemporally generated by sPLA 2 action in particular subcellular sites may in turn trigger the COX-2 induction machinery. Finally, sPLA 2 -IIE is distributed in cytoplasmic punctate compartments (Fig. 4) . Previous studies have demonstrated that other HSPG-bound sPLA 2 s, such as sPLA 2 -IIA and sPLA 2 -IID, also display a similar punctate distribution (6, 8, 10) .
Collectively, these results suggest that human sPLA 2 -IIE, like sPLA 2 -IIA and -IID (4 -8) , is capable of promoting AA release through the HSPG-shuttling pathway. Although the affinity of sPLA 2 -IIE for heparanoids is weak, a small fraction of the enzyme that binds to cell surface HSPG (Fig. 1D ) may be sufficient to elicit the cellular responses. Our previous failure to detect AA release by mouse sPLA 2 -IIE in HEK293 cells (8) might be due to its intrinsically weak enzyme activity rather than to its defect in HSPG binding, since human and mouse sPLA 2 -IIEs have well conserved cationic amino acid residues (27, 28) and display a similar subcellular distribution (Fig. 4) . This does not necessarily mean that mouse sPLA 2 -IIE is functionally a null enzyme in any cell type, since it is capable of augmenting IgE/antigen-dependent LTC 4 production (Fig. 4A) and degranulation (Fig. 4B ) in rat mastocytoma RBL-2H3 cells, even though the LTC 4 -biosynthetic action is weaker than sPLA 2 -V and -X (8). Enhanced degranulation of mast cells by sPLA 2 -IIE is compatible with our previous observation that the heparin-binding enzymes, sPLA 2 -IIA, -IID, and -V, exert this effect (29) , probably by facilitating the spatiotemporal production of fusogenic lysophospholipids. Given these findings, mouse sPLA 2 -IIE may require more restricted microdomain structures on target membranes to exert its proper enzymatic function, and such a membrane microdomain could be spatiotemporally formed in IgE/antigen-activated RBL-2H3 cells.
We have shown that the expression of sPLA 2 -IIE is markedly increased in two mouse experimental inflammation models. Induction of sPLA 2 -IIE in several tissues of LPS-treated mice (Fig. 6A) is consistent with the recent work by Suzuki et al. (28) , which demonstrated, by means of in situ hybridization, that sPLA 2 -IIE is expressed in macrophage-like cells in LPStreated, but not in control, mice. The observation that the expression of sPLA 2 -IIE is increased in mouse ears with atopic dermatitis (Fig. 6B) , together with the facts that it is expressed endogenously in mouse cultured mast cells (29) and that it enhances LTC 4 production and degranulation in a rat mast cell line (Figs. 3C and  3D ), suggests that sPLA 2 -IIE may participate in the process of inflammation involving mast cell-directed allergic reactions.
Although our present results suggest that the three related group II subfamily sPLA 2 s (IIA, IID and IIE) can be functionally redundant, it should be noted that the expression of sPLA 2 -IIE is lower than other related sPLA 2 enzymes in all tissues (27, 28) . It is now recognized that a main physiological function of sPLA 2 -IIA is the destruction of infectious bacterial membranes (19 -21) , yet the bactericidal activity of sPLA 2 -IIE is rather weaker than that of sPLA 2 -IIA (21). Therefore, it still remains elusive if sPLA 2 -IIE indeed plays a compensatory role in pathophysiological circumstances, which should be clarified by gene targeting in future.
